Upcoming Events for LENZ Therapeutics
LENZ Therapeutics, Inc. (NASDAQ: LENZ) has recently made headlines as it prepares to showcase its progress at various investor conferences. This innovative pharmaceutical company is known for its dedication to delivering VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved eye drop specifically designed for presbyopia treatment in adults. These conferences present a unique opportunity for investors to gain deeper insights into the future of LENZ and its product pipeline.
Piper Sandler 37th Annual Healthcare Conference
Details on the Conference
On December 2, 2025, LENZ Therapeutics will take part in the prestigious Piper Sandler 37th Annual Healthcare Conference. This event, held in New York City, will feature a fireside chat with company management scheduled for 3:30 PM ET. Investors can participate in live audio webcasts and arrange one-on-one meetings to discuss the future trajectory of LENZ, making it a crucial gathering for interested parties.
8th Annual Evercore Healthcare Conference
What to Expect
The following day, December 3, 2025, LENZ will further engage with the investment community at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. This conference promises insightful discussions, including a fireside chat at 1:20 PM ET, where company executives will likely outline their strategic vision for VIZZ™ and provide updates on upcoming initiatives.
Citi's 2025 Global Healthcare Conference
Engaging with Investors
December 4, 2025, marks another important date for LENZ, as they appear at Citi's 2025 Global Healthcare Conference in Miami, Florida. With a fireside chat scheduled for 10:30 AM ET, this event will provide an intimate setting for discussions, enabling potential investors to better understand the company’s goals and innovative solutions aimed at addressing the pressing issue of presbyopia.
Availability of Live Webcasts
For those unable to attend in person, LENZ Therapeutics will offer live audio webcasts of their presentations, accessible on their official website, providing a platform for wider audience engagement. A replay of these webcasts will be available for 12 months, ensuring that stakeholders can stay updated on the latest developments.
About LENZ Therapeutics
LENZ Therapeutics is more than just a pharmaceutical company; it is at the forefront of a significant healthcare innovation. Their product, VIZZ™, stands as the only FDA-approved aceclidine-based eye drop specifically aimed at treating presbyopia, a condition that affects approximately 1.8 billion people worldwide. In the United States alone, 128 million individuals are impacted. LENZ continues to focus on advancing its commercial efforts within the United States and is actively seeking international partnerships to expand access to VIZZ globally. The headquarters is based in San Diego, showcasing their commitment to innovation and growth.
Contact Information
For inquiries, you can reach out directly to Dan Chevallard at LENZ Therapeutics through their email: IR@LENZ-Tx.com. This line of communication remains open for interested investors, offering the chance to connect directly with company representatives.
Frequently Asked Questions
What is VIZZ™?
VIZZ™ is an aceclidine ophthalmologic solution designed for treating presbyopia in adults. It is the only FDA-approved eye drop of its kind.
When are the upcoming investor conferences?
The investor conferences for LENZ Therapeutics are scheduled for December 2, 3, and 4, 2025, at various locations across the United States.
How can investors listen to the webcasts?
Investors can listen to the live webcasts of the presentations on the LENZ Therapeutics official website, where replays will be available for 12 months.
Where is LENZ Therapeutics headquartered?
LENZ Therapeutics is headquartered in San Diego, California, which is at the heart of the biotech industry in the country.
How can I contact LENZ Therapeutics?
You can contact LENZ Therapeutics through their investor relations email at IR@LENZ-Tx.com for any inquiries or further information.
